Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30559769 | 0.83 | GRM5 (0.31) | GRM5 | |
| SCHEMBL16357218 | 0.83 | GRM5 (0.31) | GRM5 | |
| SCHEMBL20907232 | 0.83 | HTT (0.38) | — | |
| SCHEMBL23172302 | 0.74 | GRM5 (0.43) | GPR3DAODAPK3NTRK1PIM1 | |
| SCHEMBL13104456 | 0.73 | GPR3 (0.40) | GPR3DAOPTGS2 | |
| SCHEMBL20881064 | 0.73 | — | — | |
| SCHEMBL26732897 | 0.73 | KDM1A (0.34) | IDO1 | |
| SCHEMBL12093250 | 0.72 | HSD17B1 (0.44) | PTGS2PTGS1GRM5 | |
| SCHEMBL22380074 | 0.71 | GPR3 (0.38) | GPR3DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL5987599 | 0.71 | DAO (0.44) | GPR3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807670-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | YOAKIM CHRISTIANE | 2010-02-18 | — | — | US | disclosed |
| US-7528167-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-05-05 | — | — | US | disclosed |
| EP-1345943-B1 | INHIBITORS OF PAPILLOMA VIRUS | BOEHRINGER INGELHEIM CA LTD (CA) | 2007-03-21 | — | — | EP | disclosed |
| US-20060235010-A1 | DNA replication that interfere with the E1-E2-DNA complex during initiation of DNA replication; 1-(hydroxy, oxo, or epoxy)-3-oxo-3'-benzaminocarbonyl-4'-(carboxy or carboxylate)-1,2,3-trihydroindene-2-spiro-2'-tetrahydrofuran derivatives | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-10-19 | — | — | US | disclosed |
| US-7119099-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-10-10 | — | — | US | disclosed |
| US-20050009855-A1 | 1-(hydroxy, oxo, or epoxy)-3-oxo-3'-benzaminocarbonyl-4'-(carboxy or carboxylate)-1,2,3-trihydroindene-2-spiro-2'-tetrahydrofuran derivatives; these compounds interfere with the E1-E2-DNA complex during initiation of DNA replication | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2005-01-13 | — | — | US | disclosed |
| US-6759409-B2 | PREVENT VIRUS REPRODUCTION | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-07-06 | — | — | US | disclosed |
| EP-1345943-A2 | INHIBITORS OF PAPILLOMA VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-09-24 | — | — | EP | disclosed |
| US-20030064985-A1 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-03 | — | — | US | disclosed |
| WO-2002050082-A2 | INHIBITORS OF PAPILLOMA VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064985-A1 | Inhibitors of papilloma virus | REV1, CDKN1A, PCNA | GPR3 2937/4885DAO 2953/4885DAPK3 1154/4885 |
| US-20060235010-A1 | DNA replication that interfere with the E1-E2-DNA complex during initiation of DNA replication; 1-(hydroxy, oxo, or epoxy)-3-oxo-3'-benzaminocarbonyl-4'-(carboxy or carboxylate)-1,2,3-trihydroindene-2-spiro-2'-tetrahydrofuran derivatives | CCNE2, PCNA, POLL | GPR3 1957/4885DAO 2337/4885DAPK3 2761/4885 |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | REV1, CDKN1A, RB1 | GPR3 2911/4885DAO 3454/4885DAPK3 946/4885 |
| US-20050009855-A1 | 1-(hydroxy, oxo, or epoxy)-3-oxo-3'-benzaminocarbonyl-4'-(carboxy or carboxylate)-1,2,3-trihydroindene-2-spiro-2'-tetrahydrofuran derivatives; these compounds interfere with the E1-E2-DNA complex during initiation of DNA replication | CCNE2, CCNE1, PCNA | GPR3 1562/4885DAO 1438/4885DAPK3 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.